The discovery of oncogenic genes, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS1, has changed the therapeutic approach for selected non-small cell lung cancer (NSCLC). Here, EGFR is linked to non-small cell lung carcinoma.